SG11202003537TA - Linezolid formulations - Google Patents
Linezolid formulationsInfo
- Publication number
- SG11202003537TA SG11202003537TA SG11202003537TA SG11202003537TA SG11202003537TA SG 11202003537T A SG11202003537T A SG 11202003537TA SG 11202003537T A SG11202003537T A SG 11202003537TA SG 11202003537T A SG11202003537T A SG 11202003537TA SG 11202003537T A SG11202003537T A SG 11202003537TA
- Authority
- SG
- Singapore
- Prior art keywords
- linezolid
- formulations
- linezolid formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0457—Semi-solid forms, ointments, gels, hydrogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762587101P | 2017-11-16 | 2017-11-16 | |
| PCT/GB2018/053319 WO2019097242A1 (en) | 2017-11-16 | 2018-11-16 | Linezolid formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003537TA true SG11202003537TA (en) | 2020-05-28 |
Family
ID=64457035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003537TA SG11202003537TA (en) | 2017-11-16 | 2018-11-16 | Linezolid formulations |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11517574B2 (en) |
| EP (1) | EP3709970A1 (en) |
| JP (2) | JP7251813B2 (en) |
| KR (1) | KR20200088328A (en) |
| CN (1) | CN111432800B (en) |
| AU (1) | AU2018369696B2 (en) |
| CA (1) | CA3081449A1 (en) |
| MX (1) | MX2020004896A (en) |
| RU (1) | RU2771279C2 (en) |
| SG (1) | SG11202003537TA (en) |
| TW (1) | TWI835758B (en) |
| WO (1) | WO2019097242A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021385359A1 (en) * | 2020-11-24 | 2023-06-29 | Discgenics, Inc. | Methods and systems for treatment of intervertebral disc by intradiscal micro-needle insertion cross reference to related applications |
| CN112451475B (en) * | 2020-12-02 | 2022-04-05 | 深圳善康医疗健康产业有限公司 | Long-acting sustained-release gel for treating cavernous pulmonary tuberculosis |
| WO2023062080A1 (en) | 2021-10-12 | 2023-04-20 | Persica Pharmaceuticals Ltd. | Low back pain treatment |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5628734A (en) | 1995-03-23 | 1997-05-13 | Hatfalvi; Bela I. | Spinal needle with curved distal end and method of using said needle in a spinal injection to prevent post dural puncture headache |
| US5702717A (en) | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
| US6803485B2 (en) | 1999-02-26 | 2004-10-12 | Bracco Imaging S.P.A. | Process for the preparation of iopamidol |
| US6444813B2 (en) * | 2000-02-02 | 2002-09-03 | Pharmacia & Upjohn Company | Linezolid-crystal form II |
| AR027261A1 (en) | 2000-02-02 | 2003-03-19 | Upjohn Co | LINEZOLID CRYSTAL FORM II |
| AR031135A1 (en) | 2000-10-10 | 2003-09-10 | Upjohn Co | TOPIC ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF OCULAR INFECTIONS |
| US6500153B1 (en) | 2001-07-13 | 2002-12-31 | Children's And Women's Health Centre Of British Columbia | Syringe and needle for preventing inadvertent drug injection |
| MXPA05010002A (en) * | 2003-03-24 | 2006-03-10 | Biosphere Medical Inc | Temporary embolization using inverse thermosensitive polymers. |
| US8112159B2 (en) | 2003-10-03 | 2012-02-07 | Medtronic, Inc. | Kit for implantation of therapy elements |
| WO2005037062A2 (en) * | 2003-10-14 | 2005-04-28 | Pluromed, Inc. | Confinement of kidney-stone fragments during lithotripsy |
| ES2803516T3 (en) | 2003-10-16 | 2021-01-27 | Symed Labs Ltd | A crystalline form of linezolid |
| US20060111350A1 (en) | 2004-06-29 | 2006-05-25 | Judith Aronhime | Solid forms of linezolid and processes for preparation thereof |
| JP2007504173A (en) | 2004-06-29 | 2007-03-01 | テバ ファーマシューティカル インダストリーズ リミティド | Linezolid type IV crystals |
| US7367961B2 (en) | 2004-09-10 | 2008-05-06 | Depuy Spine, Inc. | Intradiscal injection of autologous interferon |
| US7850656B2 (en) | 2005-04-29 | 2010-12-14 | Warsaw Orthopedic, Inc. | Devices and methods for delivering medical agents |
| US20070104785A1 (en) | 2005-07-29 | 2007-05-10 | Navale Suryakant V | Tablets of linezolid form iii and processes for their preparation |
| WO2007026369A1 (en) | 2005-08-29 | 2007-03-08 | Symed Labs Limited | A novel amorphous form of linezolid |
| US8318817B2 (en) | 2008-07-21 | 2012-11-27 | Otonomy, Inc. | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| KR101367479B1 (en) * | 2008-07-21 | 2014-03-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders |
| WO2011049958A2 (en) | 2009-10-21 | 2011-04-28 | Otonomy, Inc. | Modulation of gel temperature of poloxamer-containing formulations |
| US9132207B2 (en) | 2009-10-27 | 2015-09-15 | Spine Wave, Inc. | Radiopaque injectable nucleus hydrogel compositions |
| US10189773B2 (en) | 2010-05-07 | 2019-01-29 | Medicus Biosciences, Llc | In-vivo gelling pharmaceutical pre-formulation |
| HUE057236T2 (en) * | 2010-05-31 | 2022-04-28 | Farm Rovi Lab Sa | Compositions for injectable in-situ biodegradable implants |
| CN102988274B (en) * | 2010-09-08 | 2015-01-28 | 上海市肿瘤研究所 | Sustained-release blood vessel embolic gel used for treating tumor, and preparation method thereof |
| US20120101593A1 (en) * | 2010-10-20 | 2012-04-26 | BIOS2 Medical, Inc. | Implantable polymer for bone and vascular lesions |
| US10111985B2 (en) | 2011-08-10 | 2018-10-30 | Medicus Biosciences, Llc | Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules |
| EP2606912A1 (en) | 2011-12-23 | 2013-06-26 | Central Medical Service Co., Ltd. | Contrast medium composition with contrast enhancement effect by comprising highly concentrated agent |
| WO2014013498A1 (en) * | 2012-07-17 | 2014-01-23 | Symed Labs Limited | Amorphous coprecipitates of linezolid |
| US9610396B2 (en) | 2013-03-15 | 2017-04-04 | Thermedical, Inc. | Systems and methods for visualizing fluid enhanced ablation therapy |
| ITMI20131755A1 (en) * | 2013-10-21 | 2015-04-22 | Mero S R L | BIORASSORIBLE COMPOSITION CONTAINING ANTIBACTERIAL AGENTS FOR THE TREATMENT OF LOMBAR PAIN |
| EP3099345B1 (en) | 2014-01-31 | 2018-10-10 | Cedars-Sinai Medical Center | Pigtail for optimal aortic valvular complex imaging and alignment |
| US10189870B2 (en) | 2014-04-18 | 2019-01-29 | Hangzhou Pushai Pharmaeutical Technology Co., Ltd. | Crystalline form of oxazolidinone antibiotics and preparation method, composition and use thereof |
| CN104586768A (en) * | 2014-12-30 | 2015-05-06 | 亚邦医药股份有限公司 | Linezolid-containing anti-infection pharmaceutical composition and preparation method thereof |
| EP3325624B1 (en) | 2015-07-24 | 2021-03-31 | ECM Diagnostics, Inc. | Methods for detecting and treating low-virulence infections |
| WO2018091895A1 (en) * | 2016-11-16 | 2018-05-24 | Persica Pharmaceuticals Ltd. | Antibiotic formulations for lower back pain |
| WO2019060869A1 (en) | 2017-09-25 | 2019-03-28 | Discitisdx, Inc. | Methods for treating degenerative disc disease and chronic lower back pain |
-
2018
- 2018-11-16 CA CA3081449A patent/CA3081449A1/en active Pending
- 2018-11-16 AU AU2018369696A patent/AU2018369696B2/en active Active
- 2018-11-16 CN CN201880074476.6A patent/CN111432800B/en active Active
- 2018-11-16 RU RU2020115866A patent/RU2771279C2/en active
- 2018-11-16 KR KR1020207014091A patent/KR20200088328A/en not_active Application Discontinuation
- 2018-11-16 JP JP2020526890A patent/JP7251813B2/en active Active
- 2018-11-16 EP EP18808077.4A patent/EP3709970A1/en active Pending
- 2018-11-16 SG SG11202003537TA patent/SG11202003537TA/en unknown
- 2018-11-16 TW TW107140808A patent/TWI835758B/en active
- 2018-11-16 WO PCT/GB2018/053319 patent/WO2019097242A1/en unknown
- 2018-11-16 US US16/764,468 patent/US11517574B2/en active Active
- 2018-11-16 MX MX2020004896A patent/MX2020004896A/en unknown
-
2022
- 2022-10-17 US US17/967,783 patent/US20230143410A1/en active Pending
-
2023
- 2023-03-15 JP JP2023040578A patent/JP2023075287A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021503462A (en) | 2021-02-12 |
| KR20200088328A (en) | 2020-07-22 |
| EP3709970A1 (en) | 2020-09-23 |
| TW201932112A (en) | 2019-08-16 |
| TWI835758B (en) | 2024-03-21 |
| AU2018369696A1 (en) | 2020-06-04 |
| CN111432800A (en) | 2020-07-17 |
| WO2019097242A1 (en) | 2019-05-23 |
| MX2020004896A (en) | 2020-10-19 |
| US20200352952A1 (en) | 2020-11-12 |
| RU2020115866A (en) | 2021-12-16 |
| RU2771279C2 (en) | 2022-04-29 |
| AU2018369696B2 (en) | 2024-02-01 |
| RU2020115866A3 (en) | 2021-12-16 |
| CA3081449A1 (en) | 2019-05-23 |
| CN111432800B (en) | 2023-12-15 |
| US11517574B2 (en) | 2022-12-06 |
| JP7251813B2 (en) | 2023-04-04 |
| US20230143410A1 (en) | 2023-05-11 |
| JP2023075287A (en) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273541A (en) | Formulations | |
| IL268697A (en) | Formulations | |
| IL269630A (en) | Niraparib formulations | |
| IL269621A (en) | Niraparib formulations | |
| IL273282A (en) | Niraparib formulations | |
| IL265609A (en) | Novel formulations | |
| GB201607918D0 (en) | Novel formulations | |
| IL274139A (en) | Aerosolisable formulation | |
| GB201707189D0 (en) | Novel formulations | |
| GB201701239D0 (en) | Novel formulation | |
| IL274719A (en) | Formulation | |
| GB201707188D0 (en) | Novel formulations | |
| GB201713724D0 (en) | Formulation | |
| SG11202003537TA (en) | Linezolid formulations | |
| GB201706969D0 (en) | Formulation | |
| GB201707187D0 (en) | Novel formulations | |
| GB201719464D0 (en) | Formulation | |
| IL268195A (en) | Solid fosmetpantothenate formulations | |
| GB201714461D0 (en) | Formulations | |
| GB2568045B (en) | Formulation | |
| GB201716291D0 (en) | Novel formulations | |
| GB201707564D0 (en) | Novel formulations | |
| GB201707562D0 (en) | Novel formulations | |
| GB201707190D0 (en) | Novel Formulations | |
| GB201720808D0 (en) | Formulation |